We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Tivicay

News List

European Commission approves dispersible tablets to treat paediatric HIV europeanpharmaceuticalreview
January 14, 2021
Marketing authorisation in the EU has been given to Tivicay (dolutegravir) dispersible tablets to treat HIV in certain paediatric patients.
FDA approves ViiV Healthcare’s Tivicay to treat HIV in children pharmaceutical-technology
June 16, 2020
ViiV Healthcare has received approval from the US Food and Drug Administration (FDA) for Tivicay PD (dolutegravir) tablets, in combination with other antiretroviral agents, to treat children with human immunodeficiency virus type 1 (HIV-1) infection.
FDA approves drug to treat infants and children with HIV expresspharma
June 15, 2020
The safety and effectiveness of Tivicay and Tivicay PD were supported by a trial that included 75 HIV-1–infected infants, children and adolescents four weeks to less than 18 years old.